CA2168243A1 - Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use - Google Patents

Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use

Info

Publication number
CA2168243A1
CA2168243A1 CA002168243A CA2168243A CA2168243A1 CA 2168243 A1 CA2168243 A1 CA 2168243A1 CA 002168243 A CA002168243 A CA 002168243A CA 2168243 A CA2168243 A CA 2168243A CA 2168243 A1 CA2168243 A1 CA 2168243A1
Authority
CA
Canada
Prior art keywords
liposome
methyl phosphonate
entrapped
molar ratio
phosphonate oligonucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002168243A
Other languages
French (fr)
Inventor
Ana Marie Tari
Gabriel Lopez-Berestein
Albert B. Deisseroth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2168243A1 publication Critical patent/CA2168243A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C12N2310/3125—Methylphosphonates

Abstract

A liposomal methyl phosphonate oligonucleotide composition useful in treatment of chronic myeloid leukemia comprises (a) a liposome which comprises at least one phospholipid, and (b) an antisense methyl phosphonate oligonucleotide which is entrapped in the liposome. The molar ratio of phospholipid in the liposome to the methyl phosphonate entrapped in the liposome is between about 100:1 and about 10,000:1. A process for making the composition includes the steps of (a) mixing an antisense methyl phosphonate oligonucleotide in a first organic solvent with at least one phospholipid in a second organic solvent, where the molar ratio of phospholipid to methyl phosphonate is between about 100:1 and about 10,000:1, (b) lyophilizing the mixture formed in step (a), producing a lyophilized powder. (c) hydrating the lyophilized powder. and (d) sonicating the hydrated material

Description

0 LIPOSOMAL ANTISENSE ~;l~iYL PHOSPHONATE OLIGONUCLEOTIDES
AND METHODS FOR 1~1~;1~ PREPARATION AND USE

The present invention relates to liposomal forrnulations of antisense oligonucleotides, methods of making such formulations, and methods of using themto treat cancer.

Chronic myeloid leukemia (CML) is an acquired clonal disorder involving the hematopoietic stem cell characterized by a prominent expansion of granulocytes. 90-95% of CML patients have a Philadelphia chromosome (Ph+) in the dividing bone marrow cells. The Ph+ chromosome results from a reciprocal translocation, t(9;22) (q34;ql l), which relocates the c-abl protooncogene on chromosome 9 to the breakpoint cluster region (bcr) of chromosome 22. The bcr-abl hybrid gene encodes a novel p2l0bcr-ab' fusion protein with tyrosine kinase activity. p2l0b"-ab' is of either L-6 (bcr exon II and c-abl exon "2" linkage or b2/a2 linkage) or K-28 linkage (bcr exon II and c-abl exon "~" linkage or b3/a2 linkage). p2l0b'r-ab' is believed to be involved in the pathogenesis of the disease by promoting selectively the expansion of mature myeloid progenitor cells.

The disease divides into two clinical phases: an initial chronic phase, followedby a fatal blast crisis phase. The treatment of CML is very problematic. The established methods of treatment of CML are (l~ interferon and (2) syngeneic or allogeneic bone marrow transplant. Only 25 ~ of patients develop long-term remissions. Goldman and Calabretta found that antisense oligonucleotides direcled `~ - 2 1 ~8243 . --2 --to the translation initiation site of the bcr-abl mRNA induced a reduction of p210bCr-lh~
expression and suppressed the growth of Ph+ cells but not Ph- cells. Thus the use of antisense oligonucleotides may offer a new therapeutic approach to CML.

The two main obstacles in using antisense oligonucleotides to inhibit gene expression are: (a) cellular instability and (b) cellular uptake. Natural phosphodiesters are not resistant to nuclease hydrolysis; thus high concentrations of antisense oligonucleotides are needed before any inhibition effect is observed.
Modified phosphodiester analogs, such as phosphorothioates and methyl 10 phosphonates, have been madë to overcome this nuclease hydrolysis problem, but - they have not provided a completely satisfactory solution to the problem.

The cellular uptake of antisense oligonucleotides is low. To solve this problem, two different approaches have been used. One approach is to use high 15 concentrations of antisense oligonucleotides. Even though this approach can increase the uptake of antisense oligonucleotides, it may also induce non-specific, toxic side effects. The other approach is to use physical techniques such as calcium-phosphate precipitation, DEAE-dextran mediation, or electroporation to increase the cellular uptake of oligos. These techniques are difficult to reproduce and are inapplicable in 2 o vivo.

There is a need for improved antisense compositions for use in treatment of disease, and also a need for processes for making such improved compositions.

2 5 The present invention relates to a liposomal methyl phosphonate oligonucleotide composition. The composition comprises (a) a liposome which comprises at least one phospholipid, and (b) an antisense methyl phosphonate oligonucleotide which is entrapped in the liposome. The molar ratio of phospholipids in the liposome to the methyl phosphonate entrapped in the liposome is between about 3o 100:1 and about 10.000 1.

"Entrap" and "incorporate" are used in this patent to mean that the antisense methyl phosphonate oligonucleotide is enclosed within a lipid vesicle or is otherwise contained somewhere within the walls of a liposome.

In pl~f~lled embodiments of the invention, the at least one phospholipid is selected from the group consisting of phosphatidyl cholines and phosphatidyl serines, with dioleoyl phosphatidyl choline being a particularly preferred lipid. The molar ratio of phospholipids in the liposome to the methyl phosphonate oligonucleotideen~ ed in the liposome is preferably between about 500:1 and about 5,000:1, most0 preferably about 1,000:1. The liposome is preferably llnil~mellar.

The present invention also relates to a process for making a liposomal methyl phosphonate nucleotide composition. The process includes the steps of (a) mixing an antisense methyl phosphonate oligonucleotide in a first organic solvent with at least 15 one phospholipid in a second organic solvent, where the molar ratio of phospholipid to methyl phosphonate is between about 100:1 and about 10,000:1, (b) Iyophilizing the mixture formed in step (a), thereby producin~ a Iyophilized powder, (c) hydrating the Iyophilized powder, and (d) sonicating the hydrated material.

The Iyophilized powder is preferably hydrated in step (c) to a concentration between about S mM and about 50 mM, most preferably to a concentration of aboul 10 mM. The first organic solvent is preferably dimethyl sulfoxide and the secondorganic solvent is preferably t-butanol, with t-butanol being used in excess such that the concentration of t-butanol in the mixture of step (a) is at least 95% by volume.
The present invention also relates to a method of treating chronic myeloid leukemia, comprising a~lmini~tering to a living m~mm~ n subject in an amounl effective to inhibit the growth of leukemic cells an antisense liposomal methyl phosphonate oligonucleotide composition as described above. The composition should also be useful in the treatment of other disease conditions in which similar gene 2 1 ~ ~ ~ 4 3 rearrangements are observed, including cancers of a number of types, such as cancers of the cells of the hemopoietic system.

The advantages of the invention include improved stability of the antisense oligonucleotides compositions under biologic conditions, improved uptake of the composition in cells, improved incorporation efficiency of the oligonucleotides into-liposomes, and enh~nre~ specific therapeutic effect of the antisense oligonucleotides against CML and other disease conditions in which similar gene rearrangements are observed.

Figure 1 shows growth inhibition of BV 173 and K562 cells by liposomal or free methyl phosphonate complementary to the L6 junction of the bcr-abl fusion gene mRNA. Concentrations of liposomal or free MP used varied between 100 to 500 nM. After 5 days of treatment, the cells were harvested over a 10% Ficoll solution - 15 and counted. The number of treated cells were reported as percent of the number of untreated cells. The values were reported as an average of two wells + error.

Figure 2 shows growth inhibition of K562 and HL60 cells by liposomal or free methyl phosphonate complementary to the K28 junction of the bcr-abl fusion gene mRNA. Concentrations of liposomal or free MP used varied between 100 to S00 nM. After 5 days of treatment, the cells were harvested over a 10~ Ficoll solution and counted. The number of treated cells were reported as percent of the number of untreated cells. The values were average of two wells + error.

2 5 Figure 3 shows growth inhibition of K562, EM2 and HL60 cells by liposomal or free methyl phosphonate complementary to the translation initiation site of the bcr-abl fusion gene mRNA. Concentrations of liposomal or free MP used varied between100 to 500 nM. After S days of treatment, the cells were harvested over a 10%
Ficoll solution and counted. The number of treated cells were reported as percent of the number of untreated cells. The values were average of [~o wells + error.

For optimal therapeutic use, antisense oligonucleotides have to be resistant to nuclease hydrolysis and yet retain the full capacity to form hydrogen bonds with the target mRNA bases. The present invention achieves those goals, in part through the use of methyl phosphonate derivatives of antisense oligonucleotides. Methyl 5 phosphonates are phosphodiester analogs that have substituted a methyl group at the nonbridging oxygen atom in the phosphate backbone. This structural modification makes the methyl phosphonate oligonucleotide a non-ionic analog. Thus it is insoluble in aqueous solutions and can only be dissolved in organic solvents.

10The cellular uptake of methyl phosphonates is believed to be passive diffusion, which is a slow and limitin~ process. Therefore, the present invention uses liposomes - as a carrier to avoid the limitations of the passive diffusion mech~nism and to avoid the usage of organic solvents.

15"Liposomes" is used in this patent to mean lipid-con~ining vesicles having a lipid bilayer, as well as other lipid carrier particles which can entrap antisense oligonucleotides. The liposomes can be made of one or more phospholipids, optionally including other materials such as sterols. Suitable phospholipids include phosphatidyl cholines, phosphatidyl serines, and many others that are well known in 20 this field. The liposomes can be, for example, multilamellar or have an undefined lamellar structure~ but are preferably unilamellar The techniques of the present invention are believed useful with all antisense methyl phosphonate oligonucleotides. The methyl phosphonate oligos used in the 25 examples in this patent have between 16-18 bases.

A liposomal composition in accordance with the present invention can be made by, for example, dissolving methyl phosphonate oligonucleotides with a first organic solvent. The first organic solvent preferably will be a mixture of organic solvents 30 and water, but preferably contains at least one of dimethyl sulfoxide (DMSO) or acetonitrile. Phospholipids (and optionally other materials such as sterols) are - 21 682~
-provided in a second organic solvent. The second organic solvent can also be a mixture of organic solvents and water, but preferably contains tertiary butanol. The oligonucleotides and phospholipids together with their solvents are mixed, preferably in the presence of an excess of t-butanol so that the final volume of t-butanol in the s mixture will be at least 95 % . The mixture can then be agitated, for example by being vortexed, and then frozen in, for example, an acetone/dry ice bath. The frozen mixture is then Iyophilized and subsequently hydrated, for example with a salinesolution. The liposomes that are formed are preferably sonicated.

The liposomal composition could also be prepared by other processes.

A composition of the present invention is preferably a~mini~tered to a patient parenterally, for example by intravenous, intraarterial, intramuscular, intralymphatic, intraperitoneal, subcutaneous1 intrapleural, or intrathecal injection, or may be used in ex vivo bone marrow purging. Preferred dosages are between 0.01 - 1.0 g/kg.
The a(lminictration is preferably repeated on a timed schedule until the cancer disappears or regresses, and may be in conjunction with other forrns of therapy.
The making and use of the present invention is further illustrated by the 2 0 following example.

Materials Methyl phosphonate oligonucleotides were synthesized by Genta, Inc.
Phospholipids were purchased from Avanti Polar Lipids.
Oli~onucleotide Labelin~
Methyl phosphonate oligonucleotides (MP), synthesized with a phosphodiester base at the 5' end, were labeled at 37C with [32P~3ATP at the 5' end by T4 kinase.
The MP labeling reaction was carried out for 24 h. The oligonucleotide as precipitated with ethanol at -20C overnight. After washing with 70% ethanol three 21 68~4:3 times, MP oligonucleotides were twice filtered with a Microcon-3 filter to separate the labeled oligonucleotide from free [3~P~]ATP.

Liposome Preparation s Methyl phosphonates oligonucleotides dissolved in DMSO were mixed with phospholipids in the presence of excess t-butanol so that the final volume of t-butanol - in the mixture was at least 9S % . Trace amounts of [3H]cholestanyl ether and [32P]MP
were also added to the mixture as lipid and oligonucleotide markers, respectively.
The mixture was vortexed before being frozen in an acetone/dry ice bath. The frozen mixture was lyophili7ed and hydrated with Hepes buffered saline (1 mM Hepes and 10 mM NaCl) overnight. Liposomes were twice sonicated for lO min in a bath type sonicator. Empty liposomes were prepared in a similar manner, except that no oligonucleotide was added to the lipids before the freezing process.

Separation of Free Oligonucleotides from those Incorporated in Liposomes The separation of free MP from MP incorporated in liposomes was done by loading the mixture over a 10% Ficoll solution, which was centrifuged for lO min at 2000 rpm. Aliquots of the preparation were taken before and after centrifugation for 2 o liquid scintillation counting to assess the incorporation of MP in liposomes.
Typically, MP was incorporated into liposomes ~ith a 90~ or greater efficiency Delivery of Oli~onucleotides to Cells Fifty thousand cells/well were seeded in a 24-well plate in l ml of media.
After 2 h of seeding, final concentrations of lO0-500 nM of oligos were added locells either as liposomal oligonucleotides or free oligonucleotides. After 5 days of delivery, cells were harvested over a 10% Ficoll solution. The number of cells was then counted by a Coulter counter.

Before the incorporation of MP into liposomes, it was important to find an efficient method to remove the viscous DMSO efficiently. because any traces of organic solvent such as DMSO could prevent the formation of liposomes. Two different techniques of removing DMSO were used: rotoevaporation and Iyophilization. It was found that Iyophilization can successfully remove DMSO
efficiently and quickly, whereas rotoevaporation cannot. However since DMSO has 5 a low freezing point, an excess amount of t-butanol was added to enhance the freezing process. The final volume of t-butanol should be at least 95% of the total mixture.

The lipid phosphatidylcholine (PC) was chosen for the incorporation of MP
because (1) both PC and MP are neutral molecules, so they should be compatible and 0 (2) PC is well-studied lipid and is easy to handle. To incorporate MP into liposomes, MP was mixed with dioleoyl phosphatidyl choline (DOPC) in the presence of an excess of t-butanol before the freezing and the Iyophilization processes. Various molar ratios of DOPC to MP were used. When DOPC/MP multilamellar vesicles were prepared, MP was successfully incorporated in DOPC liposomes but only with 5 less than 15% efficiency (Table 1). The incorporation efficiency was dependent on the molar ratio of DOPC to MP. The greatest efficiency of incorporation was observed when the molar ratio of DOPC to MP was 1000:1.

Table 1 Effect of molar ratio of DOPC to MP on the incorporation of MP in multilamellar vesicles.
Molar ratio of DOPC:MP Incorporation efficiency (%)a 10: 1 0 2 5 100: 1 0 500: 1 6.4 1000: 1 13.8 10000: 1 2.6 3 o a The incorporation efficiency values were obtained frorn one experiment.

-g Various techniques of preparing the DOPC/MP liposomes were studied. Table 2 shows that the efficiency of incorporation of MP in DOPC liposomes was much higher ( ~ 88%) when the liposomes were sonicated.

Table 2 Effect of sonication on the incorporation of MP in DOPC liposomes.
Methods of Liposome Preparationa Incorporation efficiency (%)b Unsonicated mllltil~mellar vesicles 17 Unsonicated extruded unilamellar vesicles 15 Sonicated llnil~m~llar vesicles 88 a The molar ratio of DOPC to MP was 1000:1.
b The incorporation efficiency values were obtained from one experiment.

2 o Sonicated, unilamellar DOPC-con~;lining liposomes were prepared to incorporate MP. The technique was identical in all cases. However~ the molar ratios of DOPC to MP were varied. Table 3 shows that the incorporation efficiency of MPwas dependent on the molar ratio of DOPC to MP.

-Table 3 Effect of molar ratio of DOPC to MP on the incorporation efficiency of MP in sonicated, unilamellar liposomes.
Molar ratio of DOPC:MP Incorporation efficiency (%)a 10: 1 13.7 100: 1 13.2 1000: 1 77-4 10000: 1 28. 1 a The incorporation efficiency values were obtained from one experiment.

Similar to the multilamellar vesicles, the highest incorporation efficiency was observed when DOPC to MP was at a 1,000:1 molar ratio.

The lipid composition was varied as well as the final hydration concentration of liposomes to test the effects of those parameters on the incorporation efficiency of MP in !iposomes. PCs with different acyl chain lengths were used as well as another 20 phospholipid (phosphatidylserine) which has a different headgroup. The liposomes were hydrated either at a final concentration of 1 mM or 10 mM. Table 4 shows that in all cases the efficiency of MP incorporation was higher when the liposomes were hydrated at 10 mM final concentration rather than at 1 mM final concentration.

-Table 4 Effect of lipid composition and the final hydration concentration of liposomes on the incorporation efficiency of MP in liposomes.
Lipid Composition Incorporation efficiency (%3 - Final Hydration Concentration of Liposomes . lmMa 10mMb Dilauryl (C12) phosphatidylcholine 38.1 83.0 + 3.0 Dimyristoyl (C14) phosphatidylcholine . 60.3 97.5 + 2.5 Dipalmitoyl (C16) phosphatidylcholine 40.3 ~ 86.5 + 3.5 Distea~oyl (C18:0) phosphatidylcholine 57.1 90.5 + 2.5 Dioleoyl (C18:1) phosphatidylcholine 34.9 92.5 + 2.5 Dioleoyl (C18:1) phosphatidylserine ND 95.0 + 2.0 a The incorporation efficiency values were obtained from one experiment. ND means not determined.
2 o b Incorporation efficiencies were reported as the average of two experiments + error.

When the liposomes were hydrated at 10 mM final concentration, at least 80 %
25 MP incorporation was observed with all the lipids tested. This showed that our method of MP incorporation into liposomes was compatible with various lipids.

Among the different lipids tested, DOPC was one of the easiest to handle.
Thus it was decided to use the composition of MP/DOPC at a molar ratio of 1/10003 o for cell studies. The liposomes were hydrated at a final concentration of 10 mM and sonicated for 15-20 min.

Inhibition by Antisense Oligonucleotide Complementary to the L6 Junction of the bcr-abl Gene Both BVl73 and K562 cells bear characteristics of Ph+ CML cells. BVl73 and K562 contain L6 and K28 junctions, respectively. Antisense oligonucleotides,5 complementary to the L6 junction of the bcr-abl gene, in the form of MP were used.
They were delivered to both BV173 and K562 cells either as liposomal or free - oligonucleotides. As shown by Figure 1, the number of BVl73 cells decreased as the concentration of liposomal or free oligonucleotides increased. When lO0 and 250 nM
of L-MP were used, the number of BV173 cells decreased to 50 and 20 percent of 10 control (untreated cells), respectively. Thus, approximately 50 and 90% growth inhibition of BV173 cells were observed. However, when the same concentrations of free MP were used, the number of BV173 cells remained about 100% of control.
Thus, when 100 or 250 nM of free MP were used, there was no growth inhibitory effect on BVl73 cells. At 500 nM of L-MP or free MP, over 80% growth inhibition 5 of BVl73 cells was observed for both cases. Under identical conditions, there was hardly any growth inhibition of K562 cells even when 500 nM of L-MP or free MP
was used. Growth inhibition was not found when empty liposomes were used (data not shown).

20 Inhibition by Antisense Oligonucleotides Complementary to the K28 Junction of the bcr-abl Gene Antisense oligos, complementary to the K28 junction of the bcr-abl gene. in the form of MP were used. Antisense oligonucleotides were delivered to both K562and HL60 cells. K562 cells were Ph+ and HL60 cells were Ph-. Five days after the25 addition of liposomal or free oligonucleotides, the cells were harvested and counted The total number of K562 cells decreased to 70, 60 or 355'c when lO0, 250 or 500nM of L-MP were used (Figure 2). This corresponded to approximately 30, 40 and 65% growth inhibition. When free MP was used, the number of K562 cells did not decrease until 500 nM concentration. The number of HL60 cells hardly changed in 30 the presence of L-MP or free MP. Again, empty liposomes did not have any inhibitory effect on the growth of K562 or HL60 cells (data not shown).

Inhibition by Antisense Oligonucleotide Complementary to the Translation Initiation Site of the bcr-abl Gene K562 and EM2 cells are Ph+ CML cells while HL60 cells are not. Antisense oligonucleotides, complementary to the translation initiation site of the bcr-abl gene, 5 in the form of MP were used. Increasing concentrations of L-MP and MP were added to all three different types of cells (Figure 3). The number of K562 cells was not affected by the presence of L-MP or free MP. However, the number of EM2 cells decreased to 30-60% of control. In other words, 40-70% inhibition was observed. When identical concentrations of free MP were used, the number of EM2 cells decreased to about 70-80% of control, which was intelL,.e~ed as 20-30%
inhibition. Thus, when the same concentrations of L-MP and free MP were added to EM2 cells, greater inhibition effect was observed with L-MP than free MP. The number of HL60 cells did not decrease till 500 nM of L-MP or free MP was used.
There was no inhibitory effect of empty liposomes on any of these cell types (data not 5 shown).

The preceding description of specific embodiments of the present invention is 20 not intended to be a complete list of every possible embodiment of the invention.
Persons skilled in this field will recognize that modifications can be made to the specific embodiments described here that would be within the scope of the present in~ention.

Claims (22)

WHAT IS CLAIMED IS:
1. A liposomal methyl phosphonate oligonucleotide composition, comprising:
a liposome consisting of a phosphatidyl choline; and an antisense methyl phosphonate oligonucleotide which is entrapped in the liposome;
where the molar ratio of phospholipids in the liposome to the methyl phosphonate oligonucleotide entrapped in the liposome is between 100:1 and 10,000:1.
2. The composition of Claim 1, where the molar ratio of phospholipids in the liposome to the methyl phosphonate oligonucleotide entrapped in the liposome is between 500:1 and 5,000:1.
3. The composition of Claim 1, where the molar ratio of phospholipids in the liposome to the methyl phosphonate oligonucleotide entrapped in the liposome is about 1,000:1.
4. The composition of any of Claims 1, 2 or 3 where the liposome is unilamellar.
5. The composition of any of the preceding Claims 1, 2, 3 or 4 where the liposome consists of dioleoyl phosphatidyl choline.
6. A process for making a liposomal methyl phosphonate oligonucleotide composition, comprising the steps of:
(a) mixing an antisense methyl phosphonate oligonucleotide in a first organic solvent with at least one phospholipid in a second organic solvent, where the molar ratio of phospholipid to methyl phosphonate oligonucleotide is between 100:1 and 10,000:1;
(b) lyophilizing the mixture formed in step (a), producing a lyophilized powder;
(c) hydrating the lyophilized powder; and (d) sonicating the hydrated material.
7. The process of Claim 6, where the lyophilized powder is hydrated in step (c) to a concentration between 5 mM and 50 mM.
8. The process of any of Claims 6 or 7, where the lyophilized powder is hydrated in step (c) to a concentration of about 10 mM.
9. The process of any of Claims 6, 7 or 8, where the first organic solvent is dimethyl sulfoxide and the second organic solvent is t-butanol, and t-butanol is used in an excess amount such that the concentration of t-butanol in the mixture of step (a) is at least 95% by volume.
10. A method of treating chronic myeloid leukemia, comprising administering to a living mammalian subject in an amount effective to inhibit the growth of leukemic cells an antisense liposomal methyl phosphonate oligonucleotide composition which comprises:
a liposome which comprises at least one phospholipid; and an antisense methyl phosphonate oligonucleotide which is entrapped in the liposome;
where the molar ratio of phospholipids in the liposome to the methyl phosphonate entrapped in the liposome is between about 100:1 and 10,000:1.
11. The method of Claim 10, where the molar ratio of phospholipids in the liposome to the methyl phosphonate oligonucleotide entrapped in the liposome is between about 500:1 and about 5,000:1.
12. The method of Claim 10, where the molar ratio of phospholipids in the liposome to the methyl phosphonate oligonucleotide entrapped in the liposome is about 1,000:1.
13. The method of Claim 10, where the liposome is unilamellar.
14. The method of Claim 10, where the liposome comprises dioleoyl phosphatidyl choline.
15. A method of treating chronic myeloid leukemia, comprising administering to a living mammalian subject in an amount effective to inhibit the growth of leukemic cells an antisense liposomal methyl phosphonate oligonucleotide composition which comprises:
a liposome consisting of a phosphatidyl choline; and an antisense methyl phosphonate oligonucleotide which is entrapped in the liposome;
where the molar ratio of phospholipids in the liposome to the methyl phosphonate oligonucleotide entrapped in the liposome is between about 100:1 and about 1,000:1.
16. The method of Claim 15, where the molar ratio of phospholipids in the liposome to the methyl phosphonate oligonucleotide entrapped in the liposome is between about 500:1 and about 5,000:1.
17. The method of Claim 15, where the molar ratio of phospholipids in the liposome to the methyl phosphonate oligonucleotide entrapped in the liposome is about 1,000:1.
18. The method of Claim 15, where the liposome is unilamellar.
19. The method of Claim 15, where the liposome consists essentially of dioleoyl phosphatidyl choline.
20. An antisense liposomal methyl phosphonate oligonucleotide composition as defined in any of Claims 1, 2, 3, 4 or 5 for use in medicine and/or veterinary median.
21. Use of an antisense liposomal methyl phosphonate oligonucleotide composition as defined in any of Claims 1, 2, 3, 4 or 5 for the manufacture of a medicament for the treatment of chronic myeloid leukemia.
22. The use of Claim 21, wherein the composition inhibits the growth of leukemic cells upon administration to a living mammalian subject.
CA002168243A 1993-07-29 1994-07-29 Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use Abandoned CA2168243A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/099,229 US5417978A (en) 1993-07-29 1993-07-29 Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
US08/099,229 1993-07-29

Publications (1)

Publication Number Publication Date
CA2168243A1 true CA2168243A1 (en) 1995-02-09

Family

ID=22273733

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002168243A Abandoned CA2168243A1 (en) 1993-07-29 1994-07-29 Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use

Country Status (10)

Country Link
US (1) US5417978A (en)
EP (1) EP0711149B1 (en)
JP (1) JPH09501160A (en)
AT (1) ATE173397T1 (en)
AU (1) AU677417B2 (en)
CA (1) CA2168243A1 (en)
DE (1) DE69414709T2 (en)
ES (1) ES2124421T3 (en)
HK (1) HK1016409A1 (en)
WO (1) WO1995003788A1 (en)

Families Citing this family (219)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420549B1 (en) 1995-06-06 2002-07-16 Isis Pharmaceuticals, Inc. Oligonucleotide analogs having modified dimers
US5643599A (en) * 1995-06-07 1997-07-01 President And Fellows Of Harvard College Intracellular delivery of macromolecules
WO1996040157A1 (en) * 1995-06-07 1996-12-19 Gen-Probe Incorporated USE OF ANTISENSE OLIGONUCLEOTIDES TO IL-6 RECEPTOR mRNA TO INHIBIT CELLULAR PROLIFERATION
US5716846A (en) * 1995-06-07 1998-02-10 Gen-Probe Incorporated Method for inhibiting cellular proliferation using antisense oligonucleotides to interleukin-6 receptor mRNA
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
WO1997044466A1 (en) 1996-05-17 1997-11-27 Endorecherche, Inc. Characterization and use of an isolated uridine diphospho-glucuronosyltransferase
US20070275921A1 (en) * 1996-06-06 2007-11-29 Isis Pharmaceuticals, Inc. Oligomeric Compounds That Facilitate Risc Loading
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
GB9618376D0 (en) 1996-09-04 1996-10-16 Ciba Geigy Ag Pharmaceutical compositions
US6977244B2 (en) * 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
GB9711919D0 (en) 1997-06-09 1997-08-06 Ciba Geigy Ag Oligonucleotide derivatives
WO1999007844A2 (en) 1997-08-07 1999-02-18 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods and compositions for treatment of restenosis
US7285288B1 (en) * 1997-10-03 2007-10-23 Board Of Regents, The University Of Texas System Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7704962B1 (en) 1997-10-03 2010-04-27 Board Of Regents, The University Of Texas System Small oligonucleotides with anti-tumor activity
JPH11292795A (en) * 1998-04-02 1999-10-26 Yamanouchi Pharmaceut Co Ltd Hiv cofactor inhibitor
US6077709A (en) 1998-09-29 2000-06-20 Isis Pharmaceuticals Inc. Antisense modulation of Survivin expression
US6743906B1 (en) * 1998-10-02 2004-06-01 Board Of Regents, The University Of Texas PPP2R1B is a tumor suppressor
CA2850318A1 (en) 1999-02-26 2000-08-31 The University Of British Columbia Trpm-2 antisense therapy
US6723338B1 (en) * 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
US7098192B2 (en) 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
US20020055479A1 (en) 2000-01-18 2002-05-09 Cowsert Lex M. Antisense modulation of PTP1B expression
US6261840B1 (en) 2000-01-18 2001-07-17 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
US20030176385A1 (en) * 2000-02-15 2003-09-18 Jingfang Ju Antisense modulation of protein expression
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
US6680172B1 (en) 2000-05-16 2004-01-20 Regents Of The University Of Michigan Treatments and markers for cancers of the central nervous system
WO2002022642A1 (en) 2000-09-14 2002-03-21 The University Of British Columbia Antisense insulin-like growth factor binding protein (igfbp)-2-oligodeoxynucleotides for prostate and other endocrine tumor therapy
KR100788092B1 (en) 2001-06-20 2007-12-21 제넨테크, 인크. Compositions and Methods for the Diagnosis and Treatment of Tumor
US20050107595A1 (en) * 2001-06-20 2005-05-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7803915B2 (en) * 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
CA2790034A1 (en) 2001-06-21 2003-01-03 Isis Pharmaceuticals, Inc. Antisense modulation of superoxide dismutase 1, soluble expression
US6964950B2 (en) 2001-07-25 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of C-reactive protein expression
US7425545B2 (en) 2001-07-25 2008-09-16 Isis Pharmaceuticals, Inc. Modulation of C-reactive protein expression
US20030096772A1 (en) 2001-07-30 2003-05-22 Crooke Rosanne M. Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7227014B2 (en) 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
DE60238143D1 (en) 2001-09-18 2010-12-09 Genentech Inc COMPOSITIONS AND METHODS FOR THE DIAGNOSIS OF TUMORS
NZ585001A (en) 2001-10-09 2011-08-26 Isis Pharmaceuticals Inc Antisense modulation of insulin-like growth factor binding protein 5 expression
US6750019B2 (en) 2001-10-09 2004-06-15 Isis Pharmaceuticals, Inc. Antisense modulation of insulin-like growth factor binding protein 5 expression
IL161733A0 (en) 2001-11-02 2005-11-20 Insert Therapeutics Inc Methods and compositions for therapeutic use of rna interference
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
MXPA04006554A (en) 2002-01-02 2005-03-31 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor.
KR101166214B1 (en) * 2002-01-17 2012-07-16 더 유니버시티 오브 브리티쉬 콜롬비아 Bispecific antisense oligonucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same
US20030180712A1 (en) 2002-03-20 2003-09-25 Biostratum Ab Inhibition of the beta3 subunit of L-type Ca2+ channels
EP2011886A3 (en) 2002-04-16 2009-02-11 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7199107B2 (en) 2002-05-23 2007-04-03 Isis Pharmaceuticals, Inc. Antisense modulation of kinesin-like 1 expression
EP1530636B1 (en) 2002-08-21 2010-08-18 The University Of British Columbia Treatment of melanoma by reduction in clusterin levels
CA2498777C (en) 2002-09-13 2015-01-13 Replicor, Inc. Non-sequence complementary antiviral oligonucleotides
EP2272958A1 (en) 2002-09-26 2011-01-12 ISIS Pharmaceuticals, Inc. Modulation of forkhead box O1A expression
ES2345330T3 (en) 2002-10-02 2010-09-21 The University Of British Columbia OLIGONUCLEOTIDOS FOR THE TREATMENT OF PROSTATE CANCER AND OTHER CANCERES.
EP1560597A4 (en) * 2002-10-29 2007-06-27 Pharmacia Corp Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
US8604183B2 (en) 2002-11-05 2013-12-10 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
CA2504720C (en) 2002-11-05 2013-12-24 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
SI1569695T1 (en) 2002-11-13 2013-08-30 Genzyme Corporation Antisense modulation of apolipoprotein b expression
CA2505801A1 (en) 2002-11-13 2004-05-27 Rosanne Crooke Antisense modulation of apolipoprotein b expression
US7144999B2 (en) 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression
EP1597366B1 (en) 2003-02-11 2012-11-21 Antisense Therapeutics Ltd Modulation of insulin like growth factor i receptor expression
US7803781B2 (en) 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
US20040185559A1 (en) 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
US7598227B2 (en) 2003-04-16 2009-10-06 Isis Pharmaceuticals Inc. Modulation of apolipoprotein C-III expression
AU2004231740A1 (en) * 2003-04-17 2004-11-04 The Trustees Of Columbia University In The City Ofnew York Desmoglein 4 is a novel gene involved in hair growth
US7399853B2 (en) 2003-04-28 2008-07-15 Isis Pharmaceuticals Modulation of glucagon receptor expression
EP2241572A3 (en) 2003-06-03 2011-04-06 Eli Lilly And Company Modulation of survivin expression
US7683036B2 (en) 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
US20070123480A1 (en) * 2003-09-11 2007-05-31 Replicor Inc. Oligonucleotides targeting prion diseases
EP2256201A3 (en) 2003-09-18 2012-07-04 Isis Pharmaceuticals, Inc. Modulation of eIF4E expression
CA2539727C (en) * 2003-10-01 2016-11-01 The University Of British Columbia Bispecific oligonucleotide for the treatment of cns malignancies
DK1678194T3 (en) 2003-10-10 2013-10-07 Alchemia Oncology Pty Ltd MODULATING SYNTHESIS AND DEGRADING HYALURONANE IN THE TREATMENT OF DISEASE
US20050191653A1 (en) 2003-11-03 2005-09-01 Freier Susan M. Modulation of SGLT2 expression
EP2412725A3 (en) 2003-11-17 2012-04-25 Genentech, Inc. Antibodies against CD79b for the treatment of tumor of hematopoeitic origin
JP2007520222A (en) 2004-01-20 2007-07-26 アイシス ファーマシューティカルズ インコーポレイテッド Regulation of glucocorticoid receptor expression
US7468431B2 (en) 2004-01-22 2008-12-23 Isis Pharmaceuticals, Inc. Modulation of eIF4E-BP2 expression
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
WO2005089268A2 (en) 2004-03-15 2005-09-29 Isis Pharmaceuticals, Inc. Compositions and methods for optimizing cleavage of rna by rnase h
AU2005231692B2 (en) * 2004-03-26 2011-01-27 Curis, Inc. RNA interference modulators of Hedgehog signaling and uses thereof
WO2005094899A1 (en) * 2004-04-02 2005-10-13 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
US20050244869A1 (en) * 2004-04-05 2005-11-03 Brown-Driver Vickie L Modulation of transthyretin expression
EP1765416A4 (en) * 2004-06-03 2010-03-24 Isis Pharmaceuticals Inc Double strand compositions comprising differentially modified strands for use in gene modulation
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
US20090048192A1 (en) * 2004-06-03 2009-02-19 Isis Pharmaceuticals, Inc. Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
US20080261904A1 (en) * 2004-06-03 2008-10-23 Balkrishen Bhat Chimeric Gapped Oligomeric Compounds
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
WO2006042112A2 (en) 2004-10-05 2006-04-20 California Institute Of Technology Aptamer regulated nucleic acids and uses thereof
EP1814595B1 (en) * 2004-11-23 2014-01-08 The University Of British Columbia Treatment of cancer with a combination of an agent that perturbs the egf signaling pathway and an oligonucleotide that reduces clusterin levels
AU2006236453B2 (en) 2005-01-25 2012-02-23 Board Of Regents, The University Of Texas System Delivery of siRNA by neutral lipid compositions
EP1855694B1 (en) 2005-02-09 2020-12-02 Sarepta Therapeutics, Inc. Antisense composition for treating muscle atrophy
JP2008535796A (en) 2005-03-10 2008-09-04 ジェネンテック・インコーポレーテッド Methods and compositions for regulating vascular integrity
RU2007138027A (en) * 2005-03-14 2009-04-20 Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем (Us) BIOACTIVE PEPTIDES FUS-1 AND COMPLEXES OF POLYPEPTIDES WITH NANOPARTICLES
EP1866414B9 (en) 2005-03-31 2012-10-03 Calando Pharmaceuticals, Inc. Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
WO2007062380A2 (en) 2005-11-21 2007-05-31 Isis Pharmaceuticals, Inc. Modulation of eif4e-bp2 expression
EP3210633B1 (en) 2006-01-26 2019-06-19 Ionis Pharmaceuticals, Inc. Compositions and their uses directed to huntingtin
AU2007243946B2 (en) 2006-04-05 2012-11-29 Curis, Inc. Method for using BOC/CDO to modulate hedgehog signaling
WO2007125173A2 (en) * 2006-05-03 2007-11-08 Baltic Technology Development, Ltd. Antisense agents combining strongly bound base - modified oligonucleotide and artificial nuclease
EP2023938A4 (en) * 2006-05-23 2010-11-10 Isis Pharmaceuticals Inc Modulation of chrebp expression
WO2008011473A2 (en) 2006-07-19 2008-01-24 Isis Pharmaceuticals, Inc. Compositions and their uses directed to hbxip
WO2008058291A2 (en) * 2006-11-09 2008-05-15 California Institute Of Technology Modular aptamer-regulated ribozymes
US8048998B2 (en) * 2007-01-19 2011-11-01 Exiqon A/S Mediated cellular delivery of LNA oligonucleotides
US20100093836A1 (en) 2007-01-29 2010-04-15 Isis Pharmaceuticals, Inc Compounds and methods for modulating protein expression
CA2676790A1 (en) 2007-02-22 2008-08-28 Genentech, Inc. Methods for detecting inflammatory bowel disease
US9381209B2 (en) * 2007-03-05 2016-07-05 The University Of British Columbia Treatment of squamous cell carcinoma with HSP27 antisense oligonucleotides and radiotherapy
US20090082217A1 (en) * 2007-07-16 2009-03-26 California Institute Of Technology Selection of nucleic acid-based sensor domains within nucleic acid switch platform
US20120165387A1 (en) 2007-08-28 2012-06-28 Smolke Christina D General composition framework for ligand-controlled RNA regulatory systems
US8367815B2 (en) * 2007-08-28 2013-02-05 California Institute Of Technology Modular polynucleotides for ligand-controlled regulatory systems
US8865667B2 (en) * 2007-09-12 2014-10-21 California Institute Of Technology Higher-order cellular information processing devices
CA2700953A1 (en) 2007-10-02 2009-04-09 Amgen Inc. Increasing erythropoietin using nucleic acids hybridizable to micro-rna and precursors thereof
WO2009060124A2 (en) * 2007-11-05 2009-05-14 Baltic Technology Development, Ltd. Use of oligonucleotides with modified bases in hybridization of nucleic acids
US9029524B2 (en) * 2007-12-10 2015-05-12 California Institute Of Technology Signal activated RNA interference
CA2715289C (en) * 2008-02-11 2019-12-24 Rxi Pharmaceuticals Corporation Modified rnai polynucleotides and uses thereof
BRPI0911332A2 (en) 2008-04-04 2019-09-24 Calando Pharmaceuticals Inc compositions and use of epas1 inhibitors
CN102112110A (en) * 2008-06-06 2011-06-29 米尔纳医疗股份有限公司 Novel compositions for the in vivo delivery of RNAi agents
US8815818B2 (en) 2008-07-18 2014-08-26 Rxi Pharmaceuticals Corporation Phagocytic cell delivery of RNAI
EP2323667A4 (en) * 2008-08-07 2012-07-25 Isis Pharmaceuticals Inc Modulation of transthyretin expression for the treatment of cns related disorders
EP3081648A1 (en) 2008-08-25 2016-10-19 Excaliard Pharmaceuticals, Inc. Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
US8796443B2 (en) 2008-09-22 2014-08-05 Rxi Pharmaceuticals Corporation Reduced size self-delivering RNAi compounds
WO2010059226A2 (en) 2008-11-19 2010-05-27 Rxi Pharmaceuticals Corporation Inhibition of map4k4 through rnai
EP2370580B1 (en) 2008-12-04 2019-09-11 CuRNA, Inc. Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1
CN102317458B (en) 2008-12-04 2018-01-02 库尔纳公司 Pass through treatment of the suppression of erythropoietin(EPO) (EPO) natural antisense transcript to EPO relevant diseases
RU2746478C2 (en) 2008-12-04 2021-04-14 КьюРНА, Инк. Treatment of tumors of diseases related to the genom-suppressor by therapy of natural transcript inhibition in anti-significant orientation regarding this gene
US9493774B2 (en) 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
WO2010090762A1 (en) 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
CN102439149B (en) 2009-02-12 2018-01-02 库尔纳公司 By suppressing to treat the related diseases of GDNF for the natural antisense transcript of the glial derived neurotrophic factor (GDNF)
PT2396038E (en) 2009-02-12 2016-02-19 Curna Inc Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
US8329882B2 (en) 2009-02-18 2012-12-11 California Institute Of Technology Genetic control of mammalian cells with synthetic RNA regulatory systems
CA2754749C (en) 2009-03-04 2019-04-30 Opko Curna, Llc Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt1
ES2656290T3 (en) 2009-03-16 2018-02-26 Curna, Inc. Treatment of diseases related to nuclear factor (derived from erythroid 2) similar to 2 (NRF2) by inhibition of natural antisense transcript to NRF2
EP2408920B1 (en) 2009-03-17 2017-03-08 CuRNA, Inc. Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
US9145555B2 (en) 2009-04-02 2015-09-29 California Institute Of Technology Integrated—ligand-responsive microRNAs
EP3248618A1 (en) 2009-04-22 2017-11-29 Massachusetts Institute Of Technology Innate immune suppression enables repeated delivery of long rna molecules
CA2760589C (en) 2009-05-01 2019-08-20 Joseph Collard Treatment of hemoglobin (hbf/hbg) related diseases by inhibition of natural antisense transcript to hbf/hbg
CN103223177B (en) 2009-05-06 2016-08-10 库尔纳公司 By suppression therapy lipid transfer and the metabolic gene relevant disease of the natural antisense transcript for lipid transfer and metabolic gene
KR101722541B1 (en) 2009-05-06 2017-04-04 큐알엔에이, 인크. Treatment of tristetraproline(ttp) related diseases by inhibition of natural antisense transcript to ttp
CA2762369C (en) 2009-05-18 2021-12-28 Joseph Collard Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
EP2432882B1 (en) 2009-05-22 2019-12-25 CuRNA, Inc. TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) and INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3
CA2764683A1 (en) 2009-05-28 2010-12-02 Joseph Collard Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
JP6128846B2 (en) 2009-06-16 2017-05-17 クルナ・インコーポレーテッド Treatment of PON1 gene-related diseases by suppression of natural antisense transcripts against paraoxonase (PON1)
EP2443237B1 (en) 2009-06-16 2017-02-22 CuRNA, Inc. Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
CN102597238B (en) 2009-06-24 2016-06-29 库尔纳公司 The relevant disease of TNFR2 is treated by suppressing for the natural antisense transcript of tumor necrosis factor receptor 2 (TNFR2)
CN102482672B (en) 2009-06-26 2016-11-09 库尔纳公司 By suppressing the natural antisense transcript treatment Down syndrome gene-associated diseases of Down syndrome gene
CN102762731B (en) 2009-08-05 2018-06-22 库尔纳公司 By inhibiting to treat insulin gene (INS) relevant disease for the natural antisense transcript of insulin gene (INS)
JP5964232B2 (en) 2009-08-25 2016-08-03 カッパーアールエヌエー，インコーポレイテッド Treatment of IQGAP-related diseases by inhibition of natural antisense transcripts against 'IQ motif-containing GTPase-activating protein' (IQGAP)
JP5887270B2 (en) 2009-09-02 2016-03-16 ジェネンテック， インコーポレイテッド Mutant SMOOTHENED AND METHOD OF USING THE SAME
EP3252068A3 (en) 2009-10-12 2018-03-14 Larry J. Smith Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
RU2539772C2 (en) 2009-10-22 2015-01-27 Дженентек, Инк. Methods and compositions for hepsin modulation of macrophage-stimulating protein
US20120244169A1 (en) 2009-11-06 2012-09-27 Fibrogen, Inc. Treatment for Radiation-Induced Disorders
CN103755809B (en) 2009-11-30 2016-06-01 霍夫曼-拉罗奇有限公司 The antibody of the tumour of SLC34A2 (TAT211=SEQID2) is expressed in treatment and diagnosis
AU2010329847A1 (en) 2009-12-11 2012-07-26 Genecode As Methods of facilitating neural cell survival using GDNF family ligand (GFL) mimetics or RET signaling pathway activators
KR101823702B1 (en) 2009-12-16 2018-01-30 큐알엔에이, 인크. Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
JP6031356B2 (en) 2009-12-23 2016-11-24 カッパーアールエヌエー，インコーポレイテッド Treatment of uncoupling protein 2 (UCP2) -related diseases by inhibition of natural antisense transcripts against UCP2.
US8940708B2 (en) 2009-12-23 2015-01-27 Curna, Inc. Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF
CA2785177C (en) 2009-12-29 2019-09-24 Curna, Inc. Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63
CN102782134B (en) 2009-12-29 2017-11-24 库尔纳公司 NRF1 relevant diseases are treated by suppressing the natural antisense transcript of the core breathing factor 1 (NRF1)
WO2011082409A2 (en) 2010-01-04 2011-07-07 Curna, Inc. Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8
WO2011085066A2 (en) 2010-01-06 2011-07-14 Curna, Inc. Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
EP2524039B1 (en) 2010-01-11 2017-11-29 CuRNA, Inc. Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg
WO2011090971A2 (en) 2010-01-19 2011-07-28 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for male reproductive disorders
RU2611192C2 (en) 2010-01-25 2017-02-21 Курна, Инк. TREATMENT OF RNase H1 RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO RNase H1
US8962586B2 (en) 2010-02-22 2015-02-24 Curna, Inc. Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcript to PYCR1
AR080243A1 (en) 2010-02-23 2012-03-21 Genentech Inc COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TUMOR TREATMENT
US9080171B2 (en) 2010-03-24 2015-07-14 RXi Parmaceuticals Corporation Reduced size self-delivering RNAi compounds
WO2011119871A1 (en) 2010-03-24 2011-09-29 Rxi Phrmaceuticals Corporation Rna interference in ocular indications
EP2550002B1 (en) 2010-03-24 2019-05-08 Phio Pharmaceuticals Corp. Rna interference in dermal and fibrotic indications
TWI644675B (en) 2010-04-09 2018-12-21 可娜公司 Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
BR112012027547B1 (en) 2010-04-29 2022-06-14 Ionis Pharmaceuticals, Inc SINGLE STRIP MODIFIED OLIGONUCLEOTIDE, COMPOSITION, AND ITS USES TO TREAT TRANSTHIRRETIN AYLOIDOSIS, REDUCE ITS SYMPTOMS, AND TO REDUCE TRANSTHIRRETIN MRNA OR PROTEIN EXPRESSION
KR101915115B1 (en) 2010-05-03 2018-11-05 큐알엔에이, 인크. Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
SG185027A1 (en) 2010-05-03 2012-11-29 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
JP5866106B2 (en) 2010-05-12 2016-02-17 コロンビア ユニヴァーシティ Method for producing enteroendocrine cells that produce and secrete insulin
TWI531370B (en) 2010-05-14 2016-05-01 可娜公司 Treatment of par4 related diseases by inhibition of natural antisense transcript to par4
US8895528B2 (en) 2010-05-26 2014-11-25 Curna, Inc. Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
US8980860B2 (en) 2010-07-14 2015-03-17 Curna, Inc. Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG
EP2625197B1 (en) 2010-10-05 2016-06-29 Genentech, Inc. Mutant smoothened and methods of using the same
CN103210086B (en) 2010-10-06 2017-06-09 库尔纳公司 NEU4 relevant diseases are treated by suppressing the natural antisense transcript of sialidase 4 (NEU4)
EP2630241B1 (en) 2010-10-22 2018-10-17 CuRNA, Inc. Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
JP6073795B2 (en) 2010-10-27 2017-02-01 カッパーアールエヌエー，インコーポレイテッド Treatment of IFRD1-related diseases by inhibition of natural antisense transcripts to interferon-related developmental regulator 1 (IFRD1)
WO2012061811A2 (en) 2010-11-05 2012-05-10 Fibrogen, Inc. Treatment method for lung remodeling diseases
KR102010598B1 (en) 2010-11-23 2019-08-13 큐알엔에이, 인크. Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog
ES2710109T3 (en) 2010-12-17 2019-04-23 Inst Nat Sante Rech Med Nucleic acids that target TCTP for use in the treatment of chemoresistant or hormone-resistant cancers
KR101697396B1 (en) 2011-02-02 2017-01-17 엑스칼리아드 파마슈티컬즈, 인코포레이티드 Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (ctgf)
WO2012109495A1 (en) 2011-02-09 2012-08-16 Metabolic Solutions Development Company, Llc Cellular targets of thiazolidinediones
CA2832972C (en) 2011-04-13 2019-04-30 Isis Pharmaceuticals, Inc. Antisense modulation of ptp1b expression
CA2838588C (en) 2011-06-09 2021-09-14 Curna, Inc. Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn
CN103597074A (en) 2011-06-16 2014-02-19 Isis制药公司 Antisense modulation of fibroblast growth factor receptor 4 expression
EP2758533B1 (en) 2011-09-20 2018-04-11 Ionis Pharmaceuticals, Inc. Antisense modulation of gcgr expression
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
CA2853373A1 (en) 2011-10-25 2013-05-02 Isis Pharmaceuticals, Inc. Antisense modulation of gccr expression
KR20140136488A (en) 2012-03-15 2014-11-28 큐알엔에이, 인크. Treatment of brain derived neurotrophic factor(bdnf) related diseases by inhibition of natural antisense transcript to bdnf
US20160136159A1 (en) 2012-09-17 2016-05-19 Chemedest Ltd. Method for Treating Peripheral Neuropathy
AU2013347990B2 (en) 2012-11-20 2018-01-18 Arbutus Biopharma Corp. Improved method for the preparation of liposome encapsulated vincristine for therapeutic use
US10052364B2 (en) 2013-03-15 2018-08-21 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for cognitive disorders
WO2014195755A1 (en) 2013-06-05 2014-12-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Hydrophobically modified antisense oligonucleotides comprising a ketal group
WO2014195754A1 (en) 2013-06-05 2014-12-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Hydrophobically modified antisense oligonucleotides comprising a triple alkyl chain
WO2014197938A1 (en) 2013-06-13 2014-12-18 Antisense Therapeutics Ltd Combination therapy
WO2015035231A1 (en) 2013-09-05 2015-03-12 Sarepta Therapeutics, Inc. Antisense-induced exon2 inclusion in acid alpha-glucosidase
US10036020B2 (en) 2013-09-19 2018-07-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Compositions and methods for inhibiting JC virus (JCV)
US10934550B2 (en) 2013-12-02 2021-03-02 Phio Pharmaceuticals Corp. Immunotherapy of cancer
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
CA2937539A1 (en) 2014-02-04 2015-08-13 Genentech, Inc. Mutant smoothened and methods of using the same
US11279934B2 (en) 2014-04-28 2022-03-22 Phio Pharmaceuticals Corp. Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
WO2015171918A2 (en) 2014-05-07 2015-11-12 Louisiana State University And Agricultural And Mechanical College Compositions and uses for treatment thereof
US10487314B2 (en) 2014-06-26 2019-11-26 The Trustees Of Columbia University In The City Of New York Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells
WO2016033424A1 (en) 2014-08-29 2016-03-03 Genzyme Corporation Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
CN107073294A (en) 2014-09-05 2017-08-18 阿克赛医药公司 Use the method for targeting TYR or MMP1 exonuclease treatment aging and skin disorder
JP7175608B2 (en) 2014-11-19 2022-11-21 ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク Osteocalcin as a treatment for age-related frailty
MA41795A (en) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc EXCLUSION OF AN EXON INDUCED BY ANTISENSE COMPOUNDS IN MYOSTATIN
EP3851531A1 (en) 2015-06-01 2021-07-21 Sarepta Therapeutics, Inc. Antisense-induced exon exclusion in type vii collagen
CA2991598A1 (en) 2015-07-06 2017-01-12 Rxi Pharmaceuticals Corporation Nucleic acid molecules targeting superoxide dismutase 1 (sod1)
US10808247B2 (en) 2015-07-06 2020-10-20 Phio Pharmaceuticals Corp. Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
TWI678213B (en) 2015-07-22 2019-12-01 美商史倍壯製藥公司 A ready-to-use formulation for vincristine sulfate liposome injection
WO2017058881A1 (en) 2015-09-28 2017-04-06 The Trustees Of Columbia University In The City Of New York Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma
WO2017062835A2 (en) 2015-10-09 2017-04-13 Sarepta Therapeutics, Inc. Compositions and methods for treating duchenne muscular dystrophy and related disorders
US11021707B2 (en) 2015-10-19 2021-06-01 Phio Pharmaceuticals Corp. Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA
AU2016349954B2 (en) 2015-11-05 2022-08-25 Antisense Therapeutics Ltd Mobilizing leukemia cells
JP2019509721A (en) 2016-02-04 2019-04-11 キュリス，インコーポレイテッド Mutant smoothened and method of using the same
AU2017254106A1 (en) 2016-04-18 2018-11-01 Sarepta Therapeutics, Inc. Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene
WO2018209288A1 (en) 2017-05-12 2018-11-15 Massachusetts Institute Of Technology Argonaute protein-double stranded rna complexes and uses related thereto
JP7394753B2 (en) 2017-10-18 2023-12-08 サレプタ セラピューティクス， インコーポレイテッド antisense oligomer compounds
EP3772928A4 (en) 2018-04-06 2021-12-29 Children's Medical Center Corporation Compositions and methods for somatic cell reprogramming and modulating imprinting
EP4326873A1 (en) 2021-04-22 2024-02-28 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4721612A (en) * 1984-04-12 1988-01-26 The Liposome Company, Inc. Steroidal liposomes
US5049388A (en) * 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
US5030442A (en) * 1987-03-30 1991-07-09 Liposome Technology, Inc. Non-crystalline minoxidil composition
US4950432A (en) * 1987-10-16 1990-08-21 Board Of Regents, The University Of Texas System Polyene microlide pre-liposomal powders
US5178875A (en) * 1991-01-14 1993-01-12 The Board Of Regents, The University Of Texas System Liposomal-polyene preliposomal powder and method for its preparation
WO1989006977A1 (en) * 1988-02-04 1989-08-10 Board Of Regents, The University Of Texas System Formulation and use of retinoids in treatment of cancer and other diseases
US5098890A (en) * 1988-11-07 1992-03-24 Temple University-Of The Commonwealth System Of Higher Education Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
US5087617A (en) * 1989-02-15 1992-02-11 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
US5112962A (en) * 1989-04-19 1992-05-12 Northwestern University Labile anchors for solid phase polynucleotide synthesis
US5100662A (en) * 1989-08-23 1992-03-31 The Liposome Company, Inc. Steroidal liposomes exhibiting enhanced stability
US5135917A (en) * 1990-07-12 1992-08-04 Nova Pharmaceutical Corporation Interleukin receptor expression inhibiting antisense oligonucleotides
CA2103377A1 (en) * 1991-06-18 1992-12-19 Bruno Calabretta Selective inhibition of leukemic cell proliferation by bcr-abl antisense oligonucleotides

Also Published As

Publication number Publication date
DE69414709D1 (en) 1998-12-24
EP0711149A1 (en) 1996-05-15
EP0711149B1 (en) 1998-11-18
WO1995003788A1 (en) 1995-02-09
JPH09501160A (en) 1997-02-04
AU677417B2 (en) 1997-04-24
US5417978A (en) 1995-05-23
DE69414709T2 (en) 1999-04-22
AU7407994A (en) 1995-02-28
ATE173397T1 (en) 1998-12-15
ES2124421T3 (en) 1999-02-01
HK1016409A1 (en) 1999-10-29

Similar Documents

Publication Publication Date Title
EP0711149B1 (en) Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
US7176302B2 (en) Liposomal phosphodiester, phosphorothioate, and p-ethoxy oligonucleotides
US6096720A (en) Liposomal oligonucleotide compositions
US7871983B2 (en) Remedy and preventive for diseases caused by NF-κB
CA2163234A1 (en) Inhibition of proliferation of vascular smooth muscle cell
KR20120013336A (en) Pharmaceutical composition containing a drug and sirna
JP2002501511A (en) High rate encapsulation of charged therapeutic agents in lipid vesicles
KR20060063788A (en) Oligonucleic acid-bearing composite and pharmaceutical composition containing the composite
JP2022506503A (en) Modified double chain oligonucleotide
US7262173B2 (en) Chemosensitizing with liposomes containing oligonucleotides
KR101678327B1 (en) WEAKLY ACIDIC pH-RESPONSIVE PEPTIDE AND LIPOSOME CONTAINING SAME
US5759519A (en) Method for the intracellular delivery of biomolecules using thiocationic lipids
JP2000506866A (en) Oligonucleotides targeted to angiotensinogen mRNA
WO1997046671A1 (en) Enhanced efficacy of liposomal antisense delivery
Tari et al. Oligonucleotide therapy for hematological malignancies
EP0925066A2 (en) Pharmaceutical compositions
CN117651771A (en) TMPRSS6 targeted siRNA for treatment of myeloproliferative disorders

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued